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HYPERTENSION COMPENDIUM
Hypertension and Prohypertensive Antineoplastic 
Therapies in Cancer Patients
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ABSTRACT: The development of a wide range of novel antineoplastic therapies has improved the prognosis for patients with 
a wide range of malignancies, which has increased the number of cancer survivors substantially. Despite the oncological 
benefit, cancer survivors are exposed to short- and long-term adverse cardiovascular toxicities associated with anticancer 
therapies. Systemic hypertension, the most common comorbidity among cancer patients, is a major contributor to the 
increased risk for developing these adverse cardiovascular events. Cancer and hypertension have common risk factors, 
have overlapping pathophysiological mechanisms and hypertension may also be a risk factor for some tumor types. Many 
cancer therapies have prohypertensive effects. Although some of the mechanisms by which these antineoplastic agents 
lead to hypertension have been characterized, further preclinical and clinical studies are required to investigate the exact 
pathophysiology and the optimal management of hypertension associated with anticancer therapy. In this way, monitoring and 
management of hypertension before, during, and after cancer treatment can be improved to minimize cardiovascular risks. 
This is vital to optimize cardiovascular health in patients with cancer and survivors, and to ensure that advances in terms of 
cancer survivorship do not come at the expense of increased cardiovascular toxicities.
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Over the last few decades, the development of novel anticancer therapies has markedly increased sur-vival rates for patients with a wide variety of malig-
nancies.1 In 2019, almost 17 million cancer survivors 
were alive in the United States alone, and this num-
ber is predicted to increase to >22 million by 2030.2 
This improved survival comes at the cost of potential 
short- and long-term toxicities associated with antican-
cer drugs. Cardiovascular toxicities are prominent and 
adversely affect outcomes in cancer survivors.3,4 While 
the cardiovascular toxic effects of older conventional 
chemotherapeutic drugs, such as anthracyclines and 
antimetabolites, have received considerable attention, 
there is a growing awareness of the importance and det-
rimental vascular effects of newer generation anticancer 
agents, particularly targeted therapies.5–8 These adverse 
vascular sequelae are a major focus of scientific and 
clinical endeavor in cardio-oncology, a rapidly growing 
subspeciality that aims to optimize cardiovascular care 
and health for patients with cancer.9,10
Systemic hypertension is one of the most frequently 
encountered vascular toxicities of many anticancer thera-
pies and is a major risk factor for cardiovascular disease 
(CVD), including heart failure, stroke, myocardial infarction, 
and cardiac arrythmias,11 as well as renal disease.12 Over 
the years, a better insight into the diverse mechanisms by 
which antineoplastic agents induce hypertension has been 
obtained, but gaps in our understanding remain. Of note, 
some anticancer therapies cause an acute rise in blood 
pressure, which may result in deterioration of preexisting 
cardiovascular conditions and lead to acute hypertension-
related complications in severe cases.13,14 Consequently, 
these hypertension-induced complications might require 
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from potentially life-saving anticancer treatment, impair-
ing patient survival. Distinct from the development of 
rapid-onset hypertension, several antineoplastic agents 
are associated with hypertension many years after the 
initial treatment period. This is reflected by an increased 
prevalence of hypertension in long-term survivors of both 
childhood and adult-onset cancers compared with the 
general population. Indeed, the prevalence of hyperten-
sion in survivors of childhood cancer exceeds 70% at the 
age of 50.15 This adds to the risk of developing CVD and 
long-term end-organ damage and increases mortality.16,17 
Importantly, these detrimental vascular effects become 
increasingly relevant as many novel targeted therapies 
lead to durable anticancer responses, contributing to 
prolonged survival in patients with cancer.16,17 Thus, the 
prevention, identification, and prompt treatment of hyper-
tension caused by antineoplastic agents is important to 
avert both short- and long-term adverse cardiovascular 
consequences.
This review highlights the interplay between cancer 
and hypertension and discusses the increased burden of 
CVD in patients with cancer. The incidence and patho-
genesis of hypertension associated with a selection of 
predominantly targeted anticancer therapies, particularly 
inhibitors of the VEGF (vascular endothelial growth fac-
tor) pathway are reviewed. Finally, clinical strategies to 
screen, monitor, and treat hypertension in the oncology 
population are discussed.
INTERPLAY BETWEEN CANCER AND 
HYPERTENSION
CVD and cancer are the most common causes of mor-
bidity and mortality in the developed world.18,19 Both 
classes of disease share numerous, potentially modifi-
able risk factors, including increased body mass index, 
diabetes,20 and tobacco use.21,22 Notably, most of these 
shared risk factors are also associated with the devel-
opment of hypertension. Population studies suggest that 
hypertension is at least partly attributable to obesity in 
around 78% of cases,23,24 and up to 80% of patients 
with type 2 diabetes develop hypertension.25 Importantly, 
a large observational cohort study demonstrated that 
hypertension is the most common comorbidity in patients 
with cancer, with a reported prevalence of 38%.26 As this 
study was published before the widespread introduction 
of many targeted therapies associated with hyperten-
sion, this is likely to be an underestimate of the current 
prevalence of hypertension among patients with cancer.
Parallel Pathophysiological Mechanisms in 
Cancer and Hypertension
The fact that cancer and hypertension frequently co-
occur and share multiple risk factors suggests that over-
lapping pathophysiological mechanisms play prominent 
roles in both conditions. The search for overlapping 
mechanisms involved in the pathogenesis of both con-
ditions has highlighted important processes (Figure 1), 
including inflammation and an increase in reactive oxy-
gen species (ROS) and oxidative stress.
Inflammatory cells and cytokines are important con-
stituents of the tumor microenvironment and targeting 
inflammatory mediators such as tumor necrosis factor-
α and interleukin-1β reduces the incidence and spread 
of cancer.27 Similarly, inflammatory cell infiltration is 
observed within the renal interstitium and the arterial 
vascular wall of hypertensive rats28,29 and inhibition of 
these inflammatory processes ameliorates hyperten-
sion.30 Clinical data from the Global Cancer Incidence, 
Mortality, and Prevalence 2018 database, which gath-
ers data from 185 countries, estimated that 13% of all 
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cancer diagnoses were attributable to chronic infec-
tions.31 Similar to the hypothesis that inflammatory acti-
vation may predispose to the development of cancer, 
elevated baseline serum levels of inflammatory mark-
ers, including C-reactive protein and interleukin-6, were 
associated with a subsequent diagnosis of hypertension 
in a study of 20 525 American women.32 A compara-
ble association between baseline inflammatory status 
and the subsequent development of hypertension has 
been observed in a meta-analysis of 142 640 patients 
recruited to cohort or nested case-control studies.33
In mice, downregulation of the tumor suppressor p53 
(mutated in ≈ 50% of malignancies) is associated with 
increased levels of oxidative stress and production of ROS. 
P53 knockout mice displayed a high subsequent inci-
dence of spontaneous lymphoma and accelerated growth 
of xenograft tumors.34 Notably, the antioxidant N-acetyl-
cysteine was an effective inhibitor of tumor growth. These 
data suggest that ROS play an important role in tumor 
development, and that ROS production may, at least partly, 
be regulated by p53.34 Furthermore, extensive experimen-
tal data from a variety of hypertensive models demonstrate 
the role of ROS and oxidative stress in the development of 
hypertension.35 However, the benefits of targeting oxida-
tive stress in patients are not well-established. A study in 
male physicians found that long-term supplementation of 
antioxidant multivitamins was modestly effective in reduc-
ing the incidence of total cancer (a composite outcome 
consisting of multiple cancer subtypes). However, this pro-
tective effect was only present in individuals with a base-
line history of cancer and not in the much larger group 
without previous cancer.36 In contrast, a recent study in 
patients with breast cancer demonstrated that antioxidant 
supplements may be associated with an increased chance 
of breast cancer recurrence, possibly by reducing the cyto-
toxicity of chemotherapy.37 Also, the preventive effects of 
antioxidant supplementation on the prevention of mortality 
from various diseases, including CVD and cancer, was not 
verified by a large Cochrane meta-analysis.38 Thus, despite 
these proposed roles of ROS in the development of can-
cer and hypertension, ROS modulation is currently not an 
established clinical treatment for the prevention or treat-
ment of either condition.
Hypertension As a Possible Risk Factor for 
Cancer
Although hypertension and cancer have overlapping 
risk factors, studies investigating the direct associations 
between hypertension and incident cancer have been 
largely inconsistent.39,40 Hypertension has been proposed 
as an independent risk factor for renal cell carcinoma 
Figure 1. The interplay between cancer and hypertension.
Cancer and hypertension frequently occur in the same patients, which is partly attributable to common risk factors and overlapping 
pathophysiological mechanisms for both conditions, including an increased body mass index (BMI), diabetes, inflammation, and oxidative stress. 
Furthermore, various anticancer therapies and adjunctive therapies exert prohypertensive effects, predisposing cancer patients to the development 
of hypertension. This risk could be further increased due to cancer-associated factors, such as inadequate pain control and anxiety. A direct 
relationship between hypertension and renal cell carcinoma has been proposed, but this has not been verified for other malignancies. Eventually, 
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(RCC) in several observational studies.39–42 One study 
of almost 300 000 patients examined the relationship 
between blood pressure, antihypertensive medication, 
and RCC within the European Prospective Investiga-
tion into Cancer and Nutrition study population.43 Over a 
mean follow-up of 6.2 years, patients with systolic blood 
pressure (SBP) ≥160 mmHg or diastolic blood pressure 
≥100 mmHg had a 2.5-fold increased risk of developing 
RCC compared with patients with SBP <120 mmHg or 
diastolic blood pressure <80 mmHg.43 Notably, an asso-
ciation between antihypertensive therapy and cancer 
was only found when blood pressure was poorly con-
trolled, suggesting that high blood pressure itself may 
predispose these individuals to the development of RCC. 
An alternative explanation could be that a confounding 
factor predisposes these patients to both cancer and 
hypertension that is difficult to control. However, the 
association between hypertension and the incidence of 
RCC was further verified in a large population cohort 
study among almost 10 million South Korean adults. 
Hypertensive individuals had an increased incidence of 
RCC (20.9 versus 9.2 cases per 100 000 person-years, 
respectively) after a follow-up of 8 years with an adjusted 
hazard ratio of 1.12.41 The underlying mechanisms pre-
disposing hypertensive individuals to developing RCC are 
thought to involve hypertension-induced chronic kidney 
disease, inflammation, and upregulation of oncogenic 
hypoxia-inducible factors and ROS.41,42 Furthermore, in 
conjunction with hypertension, other risk factors such as 
obesity, may be important in the development of RCC.42,44
In contrast to RCC, the association between hyperten-
sion and the incidence of other malignancies is less clear. 
Several studies have suggested a link between hyperten-
sion and breast cancer, particularly in postmenopausal 
women.39,45 In a meta-analysis of 30 prospective stud-
ies, hypertension was associated with a 20% increased 
breast cancer risk in postmenopausal women,45 but this 
association was not confirmed in a large Taiwanese 
population study including 111 000 individuals.46 Also, 
links between hypertension and colorectal, endometrial, 
prostate, and hepatocellular cancer have been proposed, 
but studies demonstrating a clear causal relationship 
are lacking.39,47,48 Importantly, other studies suggest that 
hypertension has little or no association with several 
other cancer types, including malignancies of the stom-
ach, gallbladder, pancreas, and lung.39,40,49,50
Increased Cardiovascular Risk in Cancer 
Survivors
Improved cancer survival has exposed a range of late 
adverse cardiovascular effects.51 This has been particu-
larly evident following childhood malignancy, as over 80% 
of children now survive at least 5 years after cancer diag-
nosis.51 Notably, these childhood and adolescent cancer 
survivors have a 7-fold increased risk of cardiovascular 
death when compared with the general population,52 
and this elevated risk persists beyond 50 years of age.53 
Also, with the exception of recurrent cancer, CVD is the 
leading cause of morbidity and mortality in this popula-
tion.54 This increased tendency to develop CVD is also 
observed in survivors of adult-onset cancers, as demon-
strated in a large registry analysis of 3.2 million cancer 
survivors in the United States.55 The risk of developing 
CVD increases over time and CVD overtakes breast can-
cer as the primary cause of mortality in older breast can-
cer survivors 10 years after the initial diagnosis.56
The marked increase in the risk for CVD may partly 
be explained by the higher prevalence of hypertension in 
patients undergoing cancer treatment or who have sur-
vived in the medium to long term. Indeed, in a study of 
≈3000 adult 10-year survivors of childhood cancer, the 
prevalence of hypertension exceeded 70% by 50 years 
of age and was 2.6-fold higher than would be expected 
based upon age-, sex-, race-, and body mass index-
specific rates in the general population.15 Additionally, a 
retrospective study found that these survivors are more 
likely to be prescribed antihypertensive medication than 
their siblings (odds ratio 1.6).57 This increased risk for the 
development of hypertension both in the short and longer 
term is likely to be primarily related to anticancer therapies. 
In a retrospective analysis of over 25 000 adult cancer 
patients in the United States, approximately one-third of 
patients developed new-onset hypertension during follow-
up, and anticancer therapy was associated with a 2- to 
3.5-fold increased risk of hypertension.58 Furthermore, 
the large Childhood Cancer Survivor Study demonstrated 
that the presence of hypertension in cancer survivors 
increased the relative risk (RR) of cardiac events, includ-
ing coronary artery disease (RR, 6.1), heart failure (RR, 
19.4), valvular disease (RR, 13.6), and cardiac arrhythmias 
(RR, 6.0) independent of cancer therapy–related risk.16 Of 
note, the risks to develop these major cardiac events were 
even higher in survivors who developed other cardiovascu-
lar risk factors or who had received anthracyclines or chest 
radiotherapy.16 These findings were supported by a study 
of 23 000 5-year survivors from the same cohort.59 For-
tunately, advances in cancer therapies and better health 
surveillance programs have reduced toxicities related to 
anticancer therapy in children, which has also improved 
their cardiovascular outcomes.59 Nonetheless, hyperten-
sion remains an important determinant of the increased 
risk of cardiac events in patients with cancer and cancer 
survivors, in whom hypertension can be preexisting or 
develop de novo in the context of cancer therapy.16,60
ANTICANCER THERAPY AND 
HYPERTENSION
In addition to possible pathophysiological associations 
between cancer and hypertension, a wide range of 
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in oncology have been shown to have prohypertensive 
effects. Awareness of hypertension induced by antineo-
plastic agents largely arose following the introduction 
of vascular endothelial growth factor inhibitors (VEGFI), 
which are associated with hypertension in a large pro-
portion of treated individuals.5 Additionally, many other 
commonly used antineoplastic agents have been asso-
ciated with an increase in blood pressure and either de 
novo hypertension or a deterioration of previously well-
controlled hypertension. Notably, patients with comor-
bidities such as CVD and uncontrolled blood pressure 
are frequently excluded from oncological clinical trials. 
Therefore, these sources of data underestimate the 
true incidence of hypertension and other cardiovascular 
toxicities.4,61–63 For most antineoplastic agents, the evi-
dence regarding their prohypertensive effects is primar-
ily derived from observational and retrospective clinical 
studies. Also, the pathophysiological mechanisms by 
which these compounds lead to an increase in blood 
pressure are mainly based on observations from preclini-
cal and in vitro studies, rather than from clinical studies or 
trials. Nonetheless, next to VEGFI (Figure 2), the prohy-
pertensive effects of a selection of predominantly novel 
orally administered targeted therapies are subsequently 
discussed, based on the available evidence from previous 
literature.7,64–67 The mechanisms underlying these prohy-
pertensive effects are displayed in Table 1 and Figure 3.
Vascular Endothelial Growth Factor Inhibitors
VEGFI are used as anticancer treatment in a wide range 
of malignancies, particularly in the metastatic setting. 
VEGFI exploit the dependency of tumors upon blood 
supply by inhibiting angiogenesis, the formation of new 
blood vessels from preexisting vasculature. Angiogenesis 
is predominantly mediated by VEGF, which is secreted by 
various cell types, including endothelial cells, fibroblasts, 
and tumor cells. In humans, the VEGF family consists of 
5 structurally related dimeric proteins: VEGF-A, VEGF-B, 
VEGF-C, VEGF-D, and PlGF (placental growth factor).96 
VEGF acts by binding to one of its 3 tyrosine kinase 
receptors (vascular endothelial growth factor receptor 
[VEGFR]1, 2, and 3), of which VEGFR2 is the main signal-
ing VEGFR (Figure 2).97 Activation of the VEGFR leads 
to multiple downstream effects, including an increase in 
capillary permeability, production of the vasodilator nitric 
oxide (NO) and promotion of vascular endothelial cell 
survival.98 In addition to promoting angiogenesis, VEGF 
also plays an important role in several other physiological 
processes, including lymphangiogenesis, the menstrual 
cycle, and wound healing.99 As depicted in Figure 2, 
four main types of VEGFI can be distinguished based 
on their mechanism of action.8 Notably, many tyrosine 
kinase inhibitors (TKI) with anti-VEGF activity interfere 
not only with VEGF signaling but also with alternative 
(proangiogenic) growth factors and receptors, such as 
the platelet-derived growth factor, fibroblast growth fac-
tor, c-Kit and Flt-3.100
Although VEGFI have led to a marked improvement 
in outcomes in various malignancies such as metastatic 
RCC,101 advanced hepatocellular carcinoma,102 cervi-
cal cancer,103 and gastrointestinal stroma cell tumors,104 
these antineoplastic agents are associated with a range 
of unwanted cardiovascular effects.4,6,8 These include 
hypertension, left ventricular systolic dysfunction, arterial 
and venous thrombosis, and cardiac arrhythmias.105–107 
Hypertension is the most frequently encountered side-
effect and occurs in 20% to 90% of treated patients, 
depending on VEGFI type and dosage.8,100 However, 
other studies reported lower incidences of hyperten-
sion (≈20%–40%).5,108 A large meta-analysis of 29 000 
patients with cancer demonstrated that patients receiv-
ing VEGF-TKI treatment had a RR of 3.78 for the devel-
opment of hypertension compared with the control 
group.105 A complicating factor in determining the pre-
cise incidence and severity of VEGFI-induced hyperten-
sion is that these studies used different versions of the 
National Cancer Institute’s Common Terminology Crite-
ria for Adverse Events to define hypertensive events.8 
Low-grade VEGFI-induced hypertension (grade 1 or 
2) occurs the most frequently and almost every patient 
experiences a rapid increase in baseline blood pressure 
within a few days after initiation of VEGFI therapy.61,68 
Nonetheless, a substantial proportion of treated patients 
develop high-grade hypertension (grade 3 or 4), ranging 
from 6% to 43%.8
The extent of the VEGFI-induced rise in blood 
pressure is dose-dependent and blood pressure nor-
malizes quickly upon drug withdrawal.69,109 Therefore, 
it is proposed that this hypertensive response reflects 
treatment efficacy and represents an on-target mech-
anism.110 Indeed, retrospective studies in patients with 
metastatic RCC or gastrointestinal stroma cell tumors 
demonstrated that the development of hypertension 
during administration of the VEGF-TKI sunitinib was 
predictive of improved survival outcomes compared 
with patients who remained normotensive.62,111 This 
relationship between VEGFI-induced hypertension 
and improved survival has not been demonstrated 
for all tumor types.112 Importantly, 2 studies demon-
strating the association between hypertension and 
improved cancer survival outcomes found that the 
use of antihypertensive agents or effective antihyper-
tensive prophylaxis did not impair antitumor treatment 
effectivity.62,113
Mechanisms Leading to VEGFI-Induced 
Hypertension
While the exact mechanisms underlying the hyperten-
sive effects of VEGFI remain elusive, several molecular 
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important modulator of vascular tone and blood pressure,114 
as demonstrated by a clinical study in which administra-
tion of recombinant human VEGF in patients with coro-
nary artery disease led to a rapid decrease in mean arterial 
pressure.115 Normally, VEGF increases the production of 
NO and prostacyclin, 2 vasodilators, by vascular endothe-
lial cells via stimulation of eNOS (endothelial NO synthase) 
activity and cytosolic phospholipase A2-mediated arachi-
donic acid release, respectively.116,117 Consequently, VEGFI 
decrease the bioavailability of these vasodilators.118,119 
On the other hand, VEGFI have been demonstrated to 
markedly increase the bioavailability of vasoconstrictors, 
particularly ET-1 (endothelin-1).69 Therefore, this causes 
an imbalance between vasodilators and vasoconstric-
tors skewed toward the latter. This enhances vasomotor 
tone and contributes to the development of hypertension. 
Polymorphisms in eNOS that are suggested to decrease 
eNOS activity and consequently lead to decreased plasma 
NO levels were associated with the development of high-
grade hypertension during sunitinib therapy.120 This further 
stresses the importance of a delicate balance between 
vasoconstrictor and vasodilator factors. Interestingly, a 
preclinical study demonstrated that ET-1 receptor antago-
nists attenuate the sunitinib-induced rise in blood pressure. 
However, these agents are currently not approved for the 
treatment of systemic hypertension in humans.121
Oxidative stress has been implicated as an addi-
tional important contributor to the hypertensive effects 
of VEGFI by inducing endothelial dysfunction, as dem-
onstrated by elevated levels of ROS in VEGFI-treated 
rats.70,122 Interestingly, recent evidence indicates that 
the increase in ET-1-mediated vasopressor response 
and ROS generation could be mediated by circulating 
endothelial nanoparticles as a result of VEGFI-asso-
ciated endothelial injury.123 However, administration of 
Tempol, a ROS scavenger, did not lead to a relevant 
attenuation of sunitinib-induced increase in blood pres-
sure in a preclinical model.121
Microvascular rarefaction (a reduction in microves-
sel density), leading to impaired microcirculation and 
increased vascular resistance, has been proposed to 
contribute to VEGFI-induced hypertension, given that 
Figure 2. Pathophysiological mechanisms underlying VEGF (vascular endothelial growth factor) inhibitor (VEGFI)-induced 
hypertension and possible therapeutic interventions.
Clinically, four different major classes of agents to inhibit VEGF signaling can be distinguished: (1) monoclonal antibodies directed against 
circulating VEGF; (2) soluble decoy receptors (VEGF-traps), scavenging freely available VEGF; (3) monoclonal antibodies against the vascular 
endothelial growth factor receptor (VEGFR); (4) TKI with anti-VEGFR activity that act on the intracellular tyrosine kinase domains of VEGFR 
to inhibit their activation. Multiple mechanisms contribute to VEGFI-induced hypertension, including an imbalance between vasoconstrictor 
(ET-1 [endothelin-1]) and vasodilator factors (nitric oxide [NO]), oxidative stress, microvascular rarefaction, renal injury, and decreased 
lymphangiogenesis. Conventional antihypertensive drugs, including calcium channel blockers and angiotensin-converting enzyme inhibitors / 
angiotensin II receptor blockers can be used in the treatment of VEGFI-induced hypertension. Additional potential treatment options include salt 
restriction, ET-1 receptor antagonists and aspirin. However, ET-1 receptor antagonists are currently not registered for the treatment of systemic 
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a moderate degree of rarefaction has been observed in 
patients receiving VEGFI.71 However, this rarefaction is 
most likely functional, rather than structural, given the 
rapidity of blood pressure increase after initiation of 
therapy and the quick blood pressure normalization after 
VEGFI withdrawal. Of note, an increase in vascular stiff-
ness has been reported during VEGFI therapy. A study 
in 84 patients with metastatic RCC demonstrated that 
sunitinib increased large artery stiffness within the first 
weeks of therapy, as measured by increased carotid-
femoral pulse wave velocity.124 This increase in vascular 
stiffness was also observed after 3 weeks of sorafenib 
treatment in another clinical study.125 Nonetheless, the 
exact contribution of vascular stiffness to the prohyper-
tensive effects of VEGFI remains unclear, as it could 
both be a cause and consequence of hypertension.125,126
It is notable that there is scarce evidence for a role 
of the renin-angiotensin-aldosterone system (RAAS) in 
VEGFI-associated hypertension. Indeed, previous clinical 
studies demonstrated that plasma renin levels decreased 
during VEGFI therapy, indicative of suppressed RAAS 
activity.69,125 Furthermore, aldosterone levels remained 
unchanged during VEGFI treatment, while the develop-
ment of hypertension in a patient who previously underwent 
a bilateral adrenalectomy suggested that aldosterone is 
not indispensable for developing hypertension in this con-
text.125,127 In a preclinical study, the angiotensin-converting 
enzyme inhibitor (ACEI) enalapril did not prevent VEGFI-
induced hypertension but ameliorated VEGFI-induced 
renal toxicity.128 One retrospective analysis of patients 
with metastatic RCC enrolled in clinical trials of anticancer 
therapy reported that survival outcomes were better for 
patients with hypertension treated with RAAS inhibitors in 
comparison to those treated with other antihypertensive 
agents.129 Although these findings are notable, they may 
be confounded by treatment selection bias.
VEGFI-induced hypertension is salt-sensitive68,130 as 
demonstrated by a preclinical study in which VEGFI-
induced rise in blood pressure was further increased 
by administration of a high-salt diet, accompanied by a 
Table 1. Anticancer Agents With Marked Prohypertensive Effects
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↓ VEGF bioavailability 93,94
Androgen synthesis inhibitors Abiraterone Mineralocorticoid activity of accumu-
lated steroid precursors
95
Androgen receptor blockers Enzalutamide Unknown NA
BRAF indicates v-raf murine sarcoma viral oncogene homolog B1; CD47, cluster of differentiation 47; cGMP, cyclic 
guanosine monophosphate; ET-1, endothelin-1; MEK, mitogen-activated protein kinase kinase; mTOR, mammalian target of 
rapamycin; NA, not applicable; NO, nitric oxide; PARP, poly ADP ribose polymerase; RET, rearranged during transfection; and 
VEGF, vascular endothelial growth factor.
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rightward shift of the renal pressure-natriuresis curve.72 
Impaired salt buffering in the skin due to inhibition of 
VEGF-C-mediated lymphangiogenesis during angio-
genesis inhibition has been proposed to underlie this 
salt-sensitive hypertension, but this concept is not sup-
ported by investigational data.72 A current clinical trial is 
investigating the effects of salt restriction on the blood 
pressure levels in VEGFI-treated patients (Netherlands 
Trial Register: URL: https://www.trialregister.nl; Unique 
identifier: NL7340). 
VEGFI-Induced Renal Toxicity
VEGF plays an important role for the maintenance of a 
healthy fenestrated endothelium in the renal glomeru-
lar apparatus, and VEGFI treatment can have nephro-
toxic effects.131 Izzedine et al propose that 2 main types 
of VEGFI-induced renal events can be distinguished, 
corresponding to the type of VEGFI therapy used. 
In a series of renal biopsies in patients with VEGFI-
associated renal toxicity, anti-VEGF-ligands (anti-VEGF 
monoclonal antibodies and soluble VEGF decoy recep-
tors) were predominantly associated with thrombotic 
microangiopathy, whereas VEGF-TKI were mainly asso-
ciated with minimal change nephropathy and/or focal 
segmental glomerulosclerosis.132,133 These renal tox-
icities may lead to proteinuria and sodium and water 
retention, further contributing to the rise in blood pres-
sure observed during VEGFI therapy.8
The adverse vascular and renal effects occurring during 
VEGFI have been termed a preeclampsia-like syndrome 
as these resemble the hallmarks of the severe pregnancy 
complication preeclampsia.121 Preeclampsia is character-
ized by hypertension, proteinuria, and increased plasma 
levels of sFlt-1 (soluble fms-like tyrosine kinase-1), a 
soluble VEGFR. As a consequence, VEGF bioavailabil-
ity is greatly diminished in preeclamptic women, and this 
is thought to play an important role in the pathogenesis 
of this disease.134 Of note, the cyclo-oxygenase inhibitor 
aspirin is an effective preventive strategy for preeclampsia 
in high-risk women as it is thought to restore the imbal-
ance between vasoconstrictor and vasodilator factors.135 
In this context, aspirin also has the potential to ameliorate 
the adverse effects of VEGFI therapy. Indeed, the ben-
eficial effects of aspirin were verified by a recent study 
in sunitinib-treated rats, but clinical benefits in VEGFI-
treated patients awaits verification.122
VEGFI-Induced Cardiac Toxicity
Treatment with VEGFI is also associated with left ven-
tricular systolic dysfunction and heart failure.136,137 The 
clinical spectrum of VEGFI-associated cardiotoxicity 
ranges from asymptomatic left ventricular dysfunction 
Figure 3. Hypothesized mechanisms underlying the prohypertensive effects of various classes of antineoplastic drugs and 
adjuvant therapies (Illustration credit: Ben Smith).
BRAF indicates v-raf murine sarcoma viral oncogene homolog B1; BTK, Bruton's tyrosine kinase; MEK, mitogen-activated protein kinase kinase; 
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and mild QTc-interval prolongation, to heart failure, car-
diogenic shock, and death.138,139 One study prospec-
tively monitored 90 RCC patients receiving sunitinib 
via echocardiography and cardiac biomarkers.140 When 
compared with baseline, 10% of these patients had a 
reduction in left ventricular ejection fraction of ≥10% 
to a value <50%, with the majority of these changes 
occurring within the first treatment cycle. Importantly, 
left ventricular dysfunction was at least partially revers-
ible with sunitinib dose modification and/or treatment 
with antihypertensive medication.140 VEGFI have the 
potential to induce direct myocardial toxic effects and 
consequently reduce the heart’s capacity to withstand 
a rise in afterload as a result of concurrent systemic 
hypertension.141 This further highlights the need for 
adequate cardiovascular monitoring and blood pressure 
control both before and during VEGFI therapy. While 
beyond the scope of this review, a detailed overview of 
the mechanisms underlying VEGFI-associated cardio-
toxicity has been published recently.142
Poly ADP Ribose Polymerase Inhibitors
PARP (poly ADP ribose polymerase) inhibitors such 
as olaparib, niraparib, rucaparib, and talazoparib have 
been approved by the United States Food and Drug 
Administration for use in breast and ovarian malignan-
cies.73 However, their efficacy has also been studied in 
pancreatic and biliary tract cancers, as well as glioblas-
toma, lung, and prostatic cancers.143 PARP inhibitors trap 
PARP1 and PARP2 at DNA damage sites and prevent 
the recruitment of additional DNA repair proteins. Con-
sequently, during the replication of tumor cells, DNA 
repair is inhibited and apoptosis and cell death ensues.144
In this drug class, only niraparib has been associated 
with hypertension.73 In the NOVA trial (Niraparib Main-
tenance Therapy in Platinum-Sensitive, Recurrent Ovar-
ian Cancer), any-grade and grade 3 or 4 hypertension 
occurred in 19% and 8% of patients treated with nirapa-
rib, respectively,145 versus 5% and 2%, respectively, in 
placebo-treated patients.145 The prohypertensive effects 
of niraparib could reflect an off-target effect: the Food 
and Drug Administration  approval summary for niraparib 
states that it can bind to dopamine, norepinephrine, and 
serotonin transporters, inhibiting their cellular uptake, 
which is accompanied by a greater ability of niraparib to 
penetrate the central nervous system than other PARP 
inhibitors.74 This has been proposed to contribute to 
the prohypertensive effects but is only speculative and 
mechanisms underlying niraparib-induced hypertension 
remain poorly understood.73
A number of trials examined the anticancer effects 
of combining PARP inhibitors with other anticancer 
agents.146,147 The addition of VEGFI to PARP inhibition in 
patients with ovarian cancer has shown promising onco-
logical effects, including longer progression-free survival 
when compared with PARP inhibition alone.148,149 This may, 
however, also increase the risk of hypertension, particularly 
in the case of niraparib. Indeed, in the phase 2 AVANOVA2 
trial (Niraparib Plus Bevacizumab Versus Niraparib Alone 
for Platinum-Sensitive, Recurrent Ovarian Cancer), 56% 
of patients receiving a combination of niraparib and the 
VEGFI bevacizumab developed hypertension, compared 
with 22% of patients receiving niraparib monotherapy.149
As noted, other PARP inhibitors have not been asso-
ciated with prohypertensive effects. In 46 patients with 
ovarian cancer, olaparib monotherapy was not associated 
with the development of hypertension.148 In fact, in the 
absence of confounding central effects, there is reason-
able mechanistic evidence to suggest that these agents 
may also have the potential to confer protective effects on 
the heart and vasculature. Indeed, PARP inhibitors have 
been demonstrated to prevent cardiomyocyte necrosis 
and reduce myocardial infarction size after cardiac reper-
fusion injury and to protect against vascular endothelial 
dysfunction in animal models, including hypertensive and 
diabetic mice.75,76 Interestingly, the PAOLA-1 trial (Olapa-
rib Plus Bevacizumab Versus Bevacizumab Alone Main-
tenance in Advanced Ovarian Cancer) of 806 patients 
reported a numerically lower incidence of hypertension 
in the olaparib and bevacizumab combination group com-
pared with bevacizumab alone (46% versus 60%).146 
Although the suggestion that PARP inhibition might con-
fer clinically meaningful cardiovascular protective effects 
in patients with cancer is an intriguing hypothesis, this 
has not been adequately investigated.
Platinum-Based Compounds
Platinum-based compounds (cisplatin, carboplatin, 
oxaliplatin) are widely used to treat testicular, ovarian, 
colorectal, bladder, and lung cancers as well as mesothe-
lioma.150 Their anticancer mechanism of action involves 
DNA uptake of platinum, with subsequent induction 
of apoptotic cell death via inhibition of transcription.151 
Hypertension is common following platinum-based 
chemotherapy, although the reported prevalence varies 
between trials.152–154 In contrast to hypertension seen 
with VEGFI, platinum therapy-associated hypertension 
tends to be a long-term effect, potentially occurring years 
after treatment. This is especially relevant in testicular 
cancer, which has a high survival rate and is the most 
common cancer in young men. One study of 1289 tes-
ticular cancer survivors reported that 53% of patients 
receiving a cumulative dose of over 850 mg cisplatin 
developed hypertension over a median follow-up of 11 
years, with an odds ratio of 2.3 compared with healthy 
controls.152 Other studies, with follow-up ranging from 7 
to 14 years, have reported a prevalence of hypertension 
ranging between 14% and 39%.153,154
These data suggest that hypertension develops and 
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platinum-based therapy. Of note, cisplatin is detectable 
in serum up to 13 years after initial exposure, which may 
provoke chronic endothelial activation. Indeed, higher 
levels of circulating platinum have been associated with 
an increased risk of hypertension.77 In patients with a 
history of testicular cancer treated with cisplatin at least 
10 years previously, microalbuminuria (closely linked to 
endothelial dysfunction) was found in 22% of patients.154
Endothelial cell activation and endothelial damage 
is thought to play an important role in the develop-
ment of platinum-associated hypertension.66,78 Exposure 
of human umbilical vein endothelial cells to cisplatin 
resulted in upregulation of intercellular adhesion mole-
cule-1, leading to increased leucocyte/endothelial inter-
action,79 while treatment of human dermal microvascular 
endothelial cells with cisplatin and bleomycin decreased 
endothelial cell survival and increased apoptosis.78 Fur-
thermore, NO production was found to be reduced in 
human umbilical vein endothelial cells exposed to carbo-
platin and paclitaxel.80 Although these are in vitro obser-
vations which require verification in a clinical study, these 
mechanisms could all lead to endothelial dysfunction, 
contributing to hypertension. In addition to hypertension, 
platinum-based therapies also predispose to chronic kid-
ney disease due to nephrotoxic effects and the devel-
opment of metabolic syndrome in the long-term, further 
increasing CVD risk.155
BRAF/MEK Inhibitors
Inhibitors of BRAF (v-raf murine sarcoma viral oncogene 
homolog B1) and inhibitors of MEK (mitogen-activated 
protein kinase kinase) are approved for use in patients 
with a range of malignancies, including melanoma, 
colorectal cancer, hepatocellular carcinoma, RCC, and 
gastrointestinal stroma cell tumors. These agents target 
BRAF (one of the three RAF kinase family members) 
and MEK, which are important kinases in the RAS-RAF-
MEK-ERK (extracellular signal-regulated kinase) sig-
naling pathway, which plays important roles in promoting 
cell proliferation, differentiation, and resistance to apop-
tosis.156 Activating BRAF mutations have been observed 
in up to 60% of melanomas, as well as in smaller pro-
portions of other malignancies.157 Multitargeted TKI, 
such as sorafenib and regorafenib, target BRAF and its 
mutant forms as well as VEGFR tyrosine kinases. These 
agents have been associated with a high prevalence of 
hypertension, which may be a result of VEGF inhibition 
as well as their effects on BRAF. In clinical trials, the 
incidence of hypertension in patients treated with more 
specific BRAF inhibitors, such as vemurafenib and dab-
rafenib, varied from 6% to 14%.158,159
Unfortunately, treatment resistance to BRAF inhibi-
tion occurs frequently, which may be due to increased 
downstream MEK activation.160 Therefore, MEK inhibi-
tors, including trametinib, were developed. Combination 
therapy of BRAF and MEK inhibitors has improved out-
comes for patients with melanoma.161 MEK inhibitors 
have also been associated with hypertension. In the 
METRIC trial (MEK Inhibition Versus Chemotherapy in 
Advanced or Metastatic BRAF-Mutant Melanoma) of 
322 patients, the incidence of grade 2 to 3 hyperten-
sion was 15% in the trametinib group versus 7% in the 
chemotherapy group.162 Additionally, a meta-analysis 
of 2704 patients treated with MEK inhibitors, either as 
monotherapy or in combination with a BRAF inhibitor, 
reported a RR of 1.5 for the development of hyperten-
sion compared with controls treated with alternative 
agents.163 Additionally, in the COMBI-d trial (Dabrafenib 
and Trametinib Versus Dabrafenib and Placebo in 
Patients With BRAF-Mutant Melanoma) of 423 patients, 
any-grade hypertension was more common in the com-
bination treatment group compared with the dabrafenib 
monotherapy group (22% versus 14%).158 However, 
high-grade hypertension (SBP ≥160 mm Hg or dia-
stolic blood pressure ≥100 mm Hg) was similar between 
both groups (4% versus 5%).158 Similarly, a meta-anal-
ysis including 2317 patients treated with combination 
BRAF/MEK inhibitor therapy reported an incidence of 
any-grade hypertension of 20% compared with 14% in 
controls treated with BRAF inhibitor monotherapy (RR 
1.5).81 This study also reported an overall incidence of 
high-grade hypertension of 8% in combination therapy 
compared with 5% in the control group.81
Although the mechanisms leading to BRAF/MEK 
inhibitor-induced hypertension are incompletely defined, 
studies in cancer cell lines could provide some insight. 
The upregulation of CD47 (cluster of differentiation 47) 
appears to be of central importance. CD47 expression 
is frequently increased in tumors164 and interacts with 
phagocytic cells to prevent cancer cell phagocytosis.165 
In cultured melanoma cells treated with BRAF/MEK 
inhibitors, rebound ERK activation induces upregulation 
of CD47 via the transcription factor nuclear respiratory 
factor-1.82 CD47 subsequently inhibits NO bioavailabil-
ity and NO-induced activation of sGC (soluble guanylate 
cyclase), thereby reducing levels of the vasodilator cGMP 
(cyclic guanosine monophosphate).83,84 This sequence 
of events might translate to endothelial dysfunction, 
increased vascular constriction, and subsequent hyper-
tension in vivo. Nonetheless, these consequences of 
CD47 upregulation have been demonstrated in mela-
noma cells only and further studies on endothelial cells 
and vascular smooth muscle cells are required.84
RET Kinase Inhibitors
Mutations in RET (rearranged during transfection), a 
receptor tyrosine kinase, are found in thyroid cancer and 
nonsmall cell lung cancer and present a potential thera-
peutic target.166 Several Food and Drug Administration-
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and cabozantinib have activity against RET; however, 
none have been approved solely on the basis of their 
anti-RET kinase action. More recently, the selective 
RET kinase inhibitors selpercatinib and pralsetinib have 
been approved for use in patients with RET mutations 
in these malignancies.85,86,167 In a phase 1 to 2 study of 
162 patients with RET-mutant medullary thyroid or RET 
fusion-positive thyroid cancer treated with selpercatinib, 
43% developed any grade hypertension. Of note, 21% of 
patients developed blood pressure ≥160/100 mm Hg.86 
Similarly, in 105 patients with nonsmall cell lung cancer, 
31% of patients treated with selpercatinib developed any 
grade hypertension.85
To the best of our knowledge, mechanisms under-
lying RET inhibitor-associated hypertension have not 
been studied. However, given the role RET kinase plays 
within the RAS-RAF-MEK-ERK pathway,87 RET inhibi-
tion may lead to rebound ERK activation similar to that 
seen with BRAF/MEK inhibition. Thus, CD47 upregula-
tion may also be important in the development of hyper-
tension with RET inhibitors. Recent studies of biopsies 
taken from patients treated with RET inhibitors have 
identified amplification of K-RAS, a member of the RAS 
family of proteins, as a potential source of resistance 
to these agents, which could be indicative of rebound 
ERK activation.168
Proteasome Inhibitors
Proteasome inhibitors (bortezomib, carfilzomib), used for 
the treatment of multiple myeloma and mantle cell lym-
phoma, induce tumor cell death by disrupting the activ-
ity of the proteasome. Proteasome inhibitors have been 
reported to have prohypertensive effects: a clinical trial 
among 929 multiple myeloma patients demonstrated 
that carfilzomib led to a longer median progression-free 
survival than bortezomib. However, this was at the cost 
of a higher incidence of all-grade (25% versus 14%) 
and high-grade (9% versus 3%) hypertension. This sug-
gests a correlation between the prohypertensive effects 
and the efficacy of these agents.169,170 Studies address-
ing the underlying pathophysiology point to decreased 
NO bioavailability, causing endothelial dysfunction.88 
Also, chronic proteasome inhibition was associated with 
impaired endothelium-dependent vasorelaxation in a 
preclinical study, indicative of endothelial dysfunction.89 
These insights are mainly derived from in vitro and animal 
studies. Not surprisingly, the vascular effects are dose- 
and treatment duration-dependent.90
BTK Inhibitors
Inhibitors of the BTK (Bruton’s tyrosine kinase) are used in 
various B-cell malignancies, including chronic lymphocytic 
leukemia and mantle cell lymphoma. In a study including 
500 patients receiving the BTK inhibitor ibrutinib, 71% of 
patients who were normotensive at baseline developed 
new hypertension and 83% of patients with baseline 
hypertension experienced worsening of hypertension.171 
However, another study in patients with chronic lympho-
cytic leukemia reported an incidence of ibrutinib-induced 
hypertension of 20% over a median follow-up of 29 
months.172 Nonetheless, BTK inhibitors are frequently 
administered for prolonged periods of time, and this 
increased tendency to develop hypertension contributes 
to long-term cardiovascular risk. Careful monitoring of 
blood pressure during BTK inhibitor therapy is essential, 
as new or worsened BTK inhibitor-induced hypertension 
was associated with an elevated risk of developing major 
adverse cardiovascular events (hazard ratio 2.17), such 
as cardiac arrhythmias and myocardial infarction.171 Pre-
liminary evidence suggests a possible correlation of BTK 
inhibitor-induced hypertension and a decrease in heat 
shock protein 70 downstream of the toll-like receptor-BTK 
signaling pathway.91 Also, inhibition of phosphatidylinositol 
3-kinase-dependent NO production has been proposed, 
but the exact mechanisms underlying BTK inhibitor-
induced hypertension have not been characterized.92
mTOR Inhibitors
Inhibitors of mTOR (mammalian target of rapamycin), 
including everolimus and sirolimus, are mainly used to 
reduce the risk of organ rejection after organ transplan-
tation. However, they remain in use in the treatment of 
several malignancies including RCC where they have 
become third-line treatment options.173 In everolimus-
treated metastatic RCC patients, 10% developed 
any-grade hypertension.93 Normally, mTOR is a potent 
stimulator of VEGF secretion via hypoxia-inducible 
factor-1α.94 Consequently, inhibition of mTOR leads to 
decreased VEGF secretion, which may have prohyper-
tensive effects similar to VEGFI.94 Indeed, other side 
effects of mTOR inhibition, such as podocyte damage 
and proteinuria, resemble VEGFI-induced toxicity.174 Of 
note, combining everolimus with the VEGF-TKI lenvatinib 
in patients with metastatic RCC was associated with all-
grade and high-grade hypertension in 41% and 14% 
of patients, respectively.93 Furthermore, mTOR inhibi-
tors impair glucose and lipid metabolism,175 and this may 
also contribute to the cardiovascular risk associated with 
these agents.
Endocrine Therapy (Antiandrogens/Aromatase 
Inhibitors)
Androgen deprivation therapy prolongs overall survival in 
patients with metastatic prostate cancer by blocking the 
trophic effects of androgens on prostate cancer cells.176 
This therapy concerns gonadotropin-releasing hormone 
agonists and therapies directly inhibiting androgen pro-
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agonists may adversely affect traditional cardiovascular 
risk factors by elevating serum lipid levels, decreasing 
insulin sensitivity and promoting obesity, without display-
ing direct hypertensive effects.177 The androgen syn-
thesis inhibitor abiraterone and the androgen receptor 
blocker enzalutamide have both been associated with 
hypertension. A large meta-analysis evaluated the car-
diovascular toxicities of abiraterone and enzalutamide 
in 8660 prostate cancer patients. All-grade and high-
grade hypertension was observed more frequently in 
the abiraterone group (26% and 7%, respectively) com-
pared with placebo (15% and 4%, respectively), and the 
same was true for the enzalutamide group (11% and 
5%, respectively) compared with placebo (4% and 2%, 
respectively).178 Importantly, these hypertensive events 
occurred irrespective of corticosteroid use, which is often 
administered concomitantly. Abiraterone inhibits testos-
terone production via inhibition of the cytochrome P450 
(CYP17) enzyme with consequent accumulation of min-
eralocorticoid precursors. This effect contributes to the 
prohypertensive effects of abiraterone and can usually be 
successfully managed with a mineralocorticoid receptor 
antagonist.95 The mechanisms underlying enzalutamide-
induced hypertension are still unclear.
Adjunctive Therapy During Cancer Treatment
Adjunctive therapies, such as corticosteroids, EPO (eryth-
ropoietin), nonsteroidal anti-inflammatory drugs, calci-
neurin inhibitors, and radiotherapy are often administered 
concurrently with antineoplastic agents. These therapies 
can contribute to the development of hypertension or 
worsening of previously controlled hypertension.65,179 
Therefore, careful monitoring is warranted when these 
are part of the anticancer therapy regime, particularly 
when co-administered with antineoplastic agents known 
to be associated with a rise in blood pressure.
Corticosteroids are an essential adjunctive therapy to 
many chemotherapy regimens for both hematologic malig-
nancies and some solid tumors.180,181 They increase the 
efficacy of some antineoplastic agents via mechanisms 
that are mostly unclear. Also, they reduce treatment-asso-
ciated side-effects and are frequently used as a form of 
palliative care.180,181 However, corticosteroids can lead to 
other significant side effects and a notable rise in blood 
pressure in conjunction with water and sodium reabsorp-
tion via mineralocorticoid receptor stimulation.182
EPO, in routine use to correct anemia caused by 
the underlying malignancy or anticancer therapy, has 
prohypertensive effects. Several mechanisms underlie 
EPO-induced hypertension, including increased blood 
viscosity, and, potentially, a skewed balance between 
vasoconstrictor and vasodilator prostaglandins with 
vascular resistance to the vasodilator effects of NO.183 
Indeed, in rats treated with EPO, elevated vascular intra-
cellular calcium concentrations were observed, which 
associated with vasoconstrictor effects that could not 
be compensated by cGMP upregulation.184
The modest prohypertensive effects of analgesic 
nonsteroidal anti-inflammatory drugs are well docu-
mented. These agents should be used with caution, 
especially in patients with hypertension, preexisting 
CVD, or in those receiving other treatments with poten-
tial cardiovascular toxic effects.185,186 Water and salt 
retention and decreased production of vasodilatory 
prostaglandins are thought to underlie the prohyperten-
sive effects.187 Although there is currently insufficient 
evidence to suggest the routine use of low-dose aspirin 
for the prevention of VEGFI-associated hypertension, 
given the beneficial role of aspirin in the treatment of 
preeclampsia and the similarities between VEGFI-asso-
ciated hypertension and preeclampsia, this is worthy of 
future investigation (Figure 2).121,134,135
Calcineurin inhibitors are used to prevent rejection 
of transplanted solid organs via inhibition of T cell func-
tion. In the field of hematology, calcineurin inhibitors are 
administered for the prevention of graft versus host dis-
ease in the context of allogenic bone marrow transplan-
tation. Calcineurin inhibitors have been shown to activate 
the RAAS and the sympathetic nervous system, to elevate 
ET-1 and ROS and to decrease NO, which all predisposes 
to hypertension.188 Also, these drugs frequently cause 
nephrotoxicity that could lead to renal sodium retention, 
further contributing to prohypertensive effects.188
Radiotherapy and/or extensive surgery of the head and 
neck can provoke hypertension and even hypertensive cri-
sis as a consequence of carotid baroreflex failure, leading to 
increased sympathetic activity and an increase in ROS.189,190 
Additionally, abdominal radiotherapy has been associated 
with renal arterial stenosis which may occasionally provoke 
severe renovascular hypertension.191 Via the promotion of 
atherosclerosis and vasculopathy, radiotherapy may fur-
ther elevate cardiovascular risk. Indeed, there is a notable 
increase in the incidence of cardiovascular and cerebro-
vascular events in patients who have undergone radiation 
therapy, particularly of the thorax, head, or neck.192
MANAGEMENT OF HYPERTENSION 
RELATED TO ANTICANCER DRUGS
The increasing number of patients with cancer presenting 
with CVD and particularly hypertension has stimulated the 
development of several cardio-oncology position state-
ments and guidelines.5,193–195 These highlight the impor-
tance of a multidisciplinary input from cardiology, (hemato-)
oncology, and cardiovascular specialists in the monitoring 
and management of CVD in this population, preferably in 
designated cardio-oncology teams. Nonetheless, the lack 
of evidence to support this guidance means there is incon-
sistency in the recommendations, and optimal manage-
ment of CVD and hypertension in these patients can pose 
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recommendations for the monitoring and management of 
hypertension before, during and after anticancer therapy 
are provided, which are summarized in Figure 4.
Before Cancer Treatment
Cardiovascular Risk Stratification and Screening
As hypertension is the most prevalent comorbidity in 
patients diagnosed with cancer,26 the management and 
monitoring of hypertension begins before commencing 
anticancer treatment. This includes a detailed clinical 
history focused on cardiovascular risk factors, includ-
ing hypertension, diabetes, and renal disease. Particular 
attention should be paid to a history of CVD, such as isch-
emic heart disease, cerebrovascular disease, peripheral 
arterial disease, and heart failure. A physical examination 
and focused investigations to screen for cardiovascu-
lar risk factors and end-organ damage should be per-
formed.63,66,106 Where possible, ambulatory blood pressure 
monitoring or home blood pressure monitoring should be 
used to identify preexisting hypertension, and office blood 
pressure should always be measured before commenc-
ing treatment.61,196 Standard laboratory determinations, 
including total cholesterol, triglycerides, fasting plasma 
glucose, and renal function should be assessed at base-
line. When anticancer agents with cardiotoxic potential 
are to be administered, an electrocardiogram and echo-
cardiogram should be performed at baseline.
It is important to achieve optimal blood pressure con-
trol before commencing antineoplastic therapy, particu-
larly in patients due to be exposed to agents known to 
have a pro-hypertensive profile and especially in those 
with baseline cardiovascular risk factors. It is particularly 
important that these management decisions are made 
collaboratively and proactively, preferably in a multidisci-
plinary cardio-oncology team, with the aim of achieving 
a balanced approach to minimize or avoid any potential 
delay in starting what may be urgent anticancer therapy. 
The aim should be to reduce the risks of adverse hyper-
tension-induced end-organ effects, and to reduce the 
need for subsequent anticancer therapy interruption or 
dose reduction because of incident hypertension.
Given that hypertension is an independent predictor of 
cardiac events in cancer patients16,60 and that numerous 
anticancer agents exert prohypertensive effects, there is 
clear clinical value in developing risk-stratification tools 
that are validated in patients with cancer. These could 
aid in the identification of those at greatest risk for the 
development of treatment-related hypertension and, in 
particular, hypertension-related end-organ complications. 
Although risk stratification tools for the development of 
cardiotoxicity due to antineoplastic therapy have been 
developed,197 specific risk stratification tools for hyperten-
sion are lacking. Therefore, clinical assessment should 
focus on conventional cardiovascular risk factors. Par-
ticular attention should be paid to the identification and 
treatment of hypertension when therapies with potential 
cardiovascular toxicity are to be given in combination.
Blood Pressure Measurement and Monitoring
Blood pressure measurement in the clinic should be per-
formed according to clinical guidelines to obtain reliable 
values.198–200 If possible, home blood pressure monitoring 
or ambulatory blood pressure monitoring should be used 
to monitor blood pressure before and during treatment, 
particularly in patients receiving or due to receive anti-
neoplastic therapy that is associated with prohypertensive 
effects.201 Special attention should be given to adequate 
control of pain and anxiety in cancer patients, as these fac-
tors can directly lead to an elevation of blood pressure.65
The criteria for the diagnosis of hypertension varies 
between international guidelines, largely as a result of dif-
ferent interpretations of data from the SPRINT (Systolic 
Blood Pressure Intervention Trial).202 This trial demon-
strated that cardiovascular outcomes in high risk patients 
were improved with intensive blood pressure control.202 The 
American College of Cardiology/American Heart Associa-
tion guidelines recommend more stringent blood pressure 
control, with antihypertensive therapy to be commenced in 
patients when blood pressure is >130/80 mm Hg in the 
context of cardiovascular risk (defined as preexisting CVD, 
a calculated 10-year cardiovascular risk of >10%, or those 
with other cardiovascular risk factors such as kidney dis-
ease or diabetes).198 The current European Society of Car-
diology guidelines and the European Society of Cardiology 
position paper on anticancer therapy cardiovascular toxicity 
recommend a treatment threshold of >140/90 mm Hg.5,200 
Importantly, the trials on which these recommendations 
were based have not been conducted in cancer patient 
populations and extrapolation of these recommendations 
requires careful consideration. Clearly, blood pressure 
targets might be more lenient for cancer patients in the 
palliative setting, for whom the short-term benefits of anti-
cancer therapy upon their quality of life might outweigh the 
increased risk of developing CVD in the long-term. In this 
population, adequate monitoring of acute hypertension-
related effects may be most important.
We generally recommend a target blood pressure of 
<130/80 mm Hg before starting anticancer treatment, 
taking these recommendations and the increased risk of 
hypertension associated with some anticancer therapies 
into consideration. While initiation of anticancer treatment 
should not be delayed to achieve strict blood pressure 
control (these may be achieved in parallel), blood pres-
sure should be at least <140/90 mm Hg before start-
ing anticancer treatments with prohypertensive effects, 
in line with the National Cancer Institute Investigational 
Drug Steering Committee’s recommendations for initiat-
ing VEGFI therapy.196 In patients with preexisting CVD, 
diabetes, or proteinuric kidney disease, blood pressure 
control should be stricter (<130/80 mm Hg) before start-
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effects. The decision-making process on antihypertensive 
therapy, blood pressure targets, and timing of anticancer 
therapy should involve input from all members of the car-
dio-oncology team to ensure optimal cardiovascular status 
is achieved before treatment.
During Cancer Treatment
Regular monitoring of blood pressure throughout cancer 
treatment is strongly advised. This is particularly relevant 
in the period soon after the initiation of anticancer ther-
apy to detect acute rises in blood pressure.61 Therefore, 
we recommend that blood pressure is measured twice 
daily via home blood pressure monitoring during the 
first treatment cycle or first period of treatment. Home 
blood pressure monitoring may not be appropriate in 
all patients203 and in this setting, blood pressure mea-
surements via the primary care physician at least once a 
week might be most suitable and these patients should 
be assessed on a case-by-case basis. If blood pressure 
levels remain within normal limits, the frequency of moni-
toring could be decreased to once every 2 to 3 weeks 
throughout treatment.196
Figure 4. Algorithm for the screening, monitoring, and treatment of blood pressure in patients with cancer receiving 
antineoplastic therapy known to be associated with hypertension.
ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BB, β-blocker; BP, blood pressure; CCB, 
dihydropyridine calcium channel blocker; CKD, chronic kidney disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; IHD, ischemic 
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Diagnosis and Management of Hypertension
While we recommend a target blood pressure <130/80 
mm Hg before anticancer therapy, we suggest that 
during cancer treatment, antihypertensive therapy 
should only be commenced in patients with new onset 
hypertension whose blood pressure exceeds 140/90 
mm Hg. In patients with preexisting CVD, diabetes or 
proteinuria, blood pressure treatment should be started 
if values exceed 130/80 mm Hg. This is suggested to 
reduce the risk of iatrogenic hypotension and to reduce 
the potential of inappropriate interruption of anticancer 
therapy.
Antihypertensive treatment may also be considered 
in patients who do not meet these definitions, but who 
have a substantial acute rise in blood pressure (eg, SBP 
rise >20 mmHg) after initiation of anticancer therapy. 
It is unclear whether absolute blood pressure or the 
magnitude of change in blood pressure from baseline 
is a more important contributor to end-organ dysfunc-
tion, but it might be that particularly this rapid increase 
in blood pressure predisposes patients to hypertensive 
complications.13,14 Furthermore, a previous meta-analysis 
demonstrated that every 10 mmHg reduction in SBP 
significantly reduces the risk of major cardiovascular 
events, such as coronary heart disease (RR, 0.8), stroke 
(RR, 0.73), and heart failure (RR, 0.72).204 It is unknown 
whether the converse holds true, and a similar size of 
increased cardiovascular risk is associated with blood 
pressure elevations of the same magnitude. This may be 
of particular relevance in patients receiving potentially 
prohypertensive anticancer therapies. This important gap 
in knowledge would aid in the recommendation of blood 
pressure treatment targets.
Currently, specific guidance on the choice of antihy-
pertensive agents in the cancer population is lacking. 
When choosing antihypertensive agents, it is important 
that careful consideration is given to drug pharmacoki-
netics and pharmacodynamics, as well as the presence 
of comorbidities and potential side effects. For example, 
nondihydropyridine calcium channel blockers (CCB), 
such as verapamil and diltiazem, should not be used in 
combination with most VEGFI as they have the poten-
tial for cytochrome P450 inhibition, which may lead to 
elevated circulating VEGFI concentrations.5,62 The choice 
of first-line antihypertensive agent generally follows 
national guidelines for hypertension management, as 
there is currently no clinical evidence to support the use 
of one class of agent over another.5,205,206
Dihydropyridine CCB such as amlodipine or nifedipine 
potently reduce arterial smooth muscle cell contractil-
ity in blood vessels.207 Therefore, given the role vascular 
dysfunction plays in the development of hypertension 
with many anticancer agents (Figure 3), CCB are likely 
to be effective in this setting. Indeed, a study of 36 
patients with nonsmall cell lung cancer, ovarian can-
cer and colorectal cancer who developed hypertension 
with bevacizumab therapy demonstrated the efficacy 
of amlodipine in achieving blood pressure control.208 
Nonetheless, it is often necessary to combine 2 or more 
antihypertensive agents to achieve satisfactory blood 
pressure levels.206 In this setting, combination of an ACEI 
or an angiotensin II receptor blocker (ARB) with a CCB 
is generally accepted as the first choice (Figure 4).5,198,205
Despite a lack of robust evidence for a major role of 
the RAAS in the prohypertensive mechanisms of most 
anticancer therapies, ACEI and ARB are frequently used 
in the treatment of VEGFI-associated hypertension and 
in the treatment of hypertension associated with other 
cancer therapies. ACEI/ARB may be used preferentially 
in cancer patients with diabetic nephropathy, left ventricu-
lar systolic dysfunction (LVSD), and cancer-therapy asso-
ciated proteinuria. Other antihypertensive agents such as 
diuretics and β-blockers may be used when ACEI/ARB 
and CCB are ineffective in normalizing blood pressure.209 
Of note, diuretics should be prescribed with caution for 
patients at risk of dehydration. Mineralocorticoid receptor 
antagonists such as eplerenone and spironolactone are 
increasingly being administered to patients with resistant 
hypertension,210 and they may be a useful option in the 
management of cancer therapy-associated hypertension 
that is unresponsive to conventional therapy.
Any decision about altering the dose or withholding 
anticancer therapy should be made via a multidisciplinary 
approach involving input from all members of the cardio-
oncology team. Generally, in patients who are symptom-
atic or have new evidence of end organ damage, dose 
reduction or temporary withdrawal of anticancer therapy 
should be considered. In cases of severe hypertension 
(≥160/100 mm Hg), temporary withdrawal of anticancer 
therapy until adequate blood pressure control is achieved 
is recommended (Figure 4). Notably, careful follow-up of 
the efficacy and tolerability of antihypertensive drugs is 
warranted to monitor the occurrence of rebound hypo-
tension, particularly during off-treatment periods or after 
definite termination of the anticancer therapy.
After Cancer Treatment
As cancer treatments continue to improve cancer progno-
sis, there is a growing clinical need for robust guidelines 
for long-term monitoring and management of CVD and 
risk factors in cancer survivors. However, current recom-
mendations mainly focus on cardiovascular screening 
and monitoring of cardiac function before or during treat-
ment.194,211 To date, the most comprehensive recommen-
dations for the monitoring of cardiovascular risk factors 
and CVD have been focused on survivors of hematologic 
malignancies who have undergone stem cell transplanta-
tion.212,213 These guidelines recommend regular screening 
for cardiovascular risk factors following the completion of 
anticancer therapy, including obesity, hypertension, and dia-
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survivor population are lacking. We suggest that cancer 
survivors should have hypertension managed strictly and 
similarly to individuals with other cardiovascular risk factors. 
Therefore, we endorse a diagnostic and treatment blood 
pressure threshold of ≥130/80 mm Hg for all patients who 
have received prior anticancer drug therapy.
CONCLUSIONS
The development of novel anticancer therapies has sub-
stantially improved the prognosis for patients with a wide 
variety of malignancies. Despite these favorable out-
comes, many of these drugs induce a systemic hyper-
tensive response during therapy that can limit the safe 
delivery of anticancer treatment. Furthermore, the rapidly 
growing number of cancer survivors are at increased risk 
from end-organ complications of hypertension. While 
there are shared risk factors and overlapping patho-
physiological mechanisms underlying both cancer and 
hypertension, the precise mechanisms underlying pro-
hypertensive effects of novel classes of antineoplastic 
agents remain incompletely defined. Careful assessment 
of blood pressure, cardiovascular risk factors, and poten-
tial end-organ effects is essential before, during, and 
after anticancer treatment. Currently, specific guidelines 
for screening, monitoring, and treatment of hyperten-
sion in the general oncological population are lacking 
but highly warranted. A collaborative approach between 
cardiologists, (hemato)-oncologists, and cardiovascular 
specialists remains vital in the day-to-day management of 
patients with cancer and hypertension. This team-based 
approach, including basic scientists, remains fundamen-
tal for the design of appropriate preclinical studies and 
clinical trials for future directions (Table 2) to better guide 
these complex intertwined issues. Only by doing so, will 
the unprecedented anticancer effects of novel and con-
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